S&P Futures
3,865.50 -57.25 (-1.46%) Dow Futures
31,024.00 -416.00 (-1.32%) Nasdaq Futures
11,742.00 -193.50 (-1.62%) Russell 2000 Futures
1,748.80 -24.00 (-1.35%) Crude Oil
107.42 -2.17 (-1.98%) Gold
1,823.00 +7.10 (+0.39%)
SCYNEXIS, Inc. (SCYX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1400 |
| Open | 2.1300 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1000 |
| Day's Range | 2.0600 - 2.2100 |
| 52 Week Range | 1.8100 - 10.2500 |
| Volume | |
| Avg. Volume | 319,506 |
| Market Cap | 69.069M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2040 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SCYX
Related Research
- SCYNEXIS, Inc.Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.RatingFair ValueEconomic Moat20 hours agoArgus Research
- Zacks
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurrent VVC is anticipated by end of 2022.As of May 2022, BREXAFEMME was covered by commercial insurance plans representing 93 million, or 55% of commercially insured lives.SCYNEXIS initiated MARIO, a global Phase 3 study to evaluate ibrexafungerp
- GlobeNewswire
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who were either intolerant to standard antifungal therapy or experienced refractory infections despite treatment.In the study, ibrexafungerp was generally safe and well-tolerated with findings consistent with the existing
